Evidence map›Paper›PMID 26753992›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2016

Natural history of human papillomavirus infection in non-vaccinated young males: low clearance probability in high-risk genotypes.

T Cai, G Perletti, F Meacci, V Magri, P Verze, A Palmieri, S Mazzoli, R Santi, G Nesi, V Mirone and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

T CaiDepartment of Urology, Santa Chiara Regional Hospital, Largo Medaglie d'Oro, 9, 38123, Trento, Italy. ktommy@libero.it.
G PerlettiBiomedical Research Division, Department of Theoretical and Applied Sciences, University of Insubria, Varese, Italy.
F MeacciSexually Transmitted Diseases Centre, Santa Maria Annunziata Hospital, Florence, Italy.
V MagriUrology Clinic, Istituti Clinici di Perfezionamento, Milan, Italy.
P VerzeDepartment of Urology, University Federico II of Naples, Naples, Italy.
A PalmieriDepartment of Urology, University Federico II of Naples, Naples, Italy.
S MazzoliSexually Transmitted Diseases Centre, Santa Maria Annunziata Hospital, Florence, Italy.
R SantiDivision of Pathological Anatomy, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
G NesiDivision of Pathological Anatomy, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy.
V MironeDepartment of Urology, University Federico II of Naples, Naples, Italy.
R BartolettiDepartment of Urology, University of Florence, Florence, Italy.
University of Florence · ITUniversity of Naples Federico II · ITOspedale Santa Maria Annunziata · ITIstituti Clinici di Perfezionamento · ITOspedale Santa Chiara · ITUniversity of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we aimed to investigate the clearance of type-specific genital human papillomavirus (HPV) infection in heterosexual, non-HPV-vaccinated males whose female partners were positive to HPV DNA tests. All consecutive men attending the same sexually transmitted diseases (STD) centre between January 2005 and December 2006 were considered for this study. All subjects (n = 1009) underwent a urologic visit and microbiological tests on first void, midstream urine and total ejaculate samples. One hundred and five patients were positive for HPV DNA (10.4 %; mean age: 34.8 ± 5.8 years) and consented to clinical examination and molecular diagnostic assays for HPV detection scheduled every 6 months (median surveillance period of 53.2 months). HPV genotypes were classified as high risk, probable high risk and low risk. HPV-positive samples which did not hybridise with any of the type-specific probes were referred to as positive non-genotypeable. At enrollment, the distribution of HPV genotypes was as follows: high-risk HPV (n = 37), probable high-risk HPV (n = 6), low-risk HPV (n = 23) and non-genotypeable HPV (n = 39). A high HPV genotype concordance between stable sexual partners emerged (kappa = 0.92; p < 0.001). At the end of the study, 71/105 (67.6 %) subjects were negative for HPV (mean virus clearance time: 24.3 months). With regard to the HPV genotype, virus clearance was observed in 14/37 (37.8 %) high-risk HPV cases, 6/6 (100 %) probable high-risk HPV cases, 20/23 (86.9 %) low-risk HPV cases and 31/39 (79.5 %) non-genotypeable cases. The high-risk HPV genotypes showed the lowest rate and probability of viral clearance (p < 0.001). In our series, high-risk HPV infections were more likely to persist over time when compared with other HPV genotypes.

Indexed as

AdultAge FactorsAlphapapillomavirusFemaleGenotypeHumansMalePapillomavirus InfectionsPublic Health SurveillanceRisk FactorsSexual BehaviorSexually Transmitted DiseasesSexual PartnersViral Load

Identifiers

PMID26753992
OpenAlexW2239129102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.